knowledge -WSS

knowledge

author：explore 2025-10-01 21:35:31 - browse：9

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： How the political right came to back psychedelics to treat trauma

hotspot

WSS

ACIP vaccine advisory panel sees its vacancies filled

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Charles Manson follower Leslie Van Houten released from prison after 53 years

Long Covid research funding gets a major boost from NIH

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Peter Hotez and the public health issue of online harassment

Long Covid research funding gets a major boost from NIH

Wildfire smoke exposes gaps in outdoor worker protections

HCA discloses massive data breach affecting 11 million patients

United colonoscopy coverage change 'may cost lives,' doctors say

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

How one medical school became remarkably diverse

Petition to FDA: Get the lead out of consumer hair dyes

BioMarin wins approval for gene therapy to treat hemophilia A

Iowa House, Senate pass 6

knowledge

Juul documents reveal insider tactics on political lobbying

Congress considering partial increase for doctor pay in Medicare

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Palantir health business leans on meeting customers’ needs

Why don't Americans have at

N.Y. state detects polio case, first in the U.S. since 2013

focus

hotspot

leisure time

focus